Telix Pharmaceuticals (TLPPF) to Announce Quarterly Earnings on Thursday

Telix Pharmaceuticals (OTCMKTS:TLPPF) is projected to issue its results before the market opens on Thursday, August 20th. Analysts expect Telix Pharmaceuticals to post earnings of $0.0447 per share and revenue of $479.6290 million for the quarter.

Telix Pharmaceuticals Stock Performance

OTCMKTS TLPPF opened at $11.50 on Tuesday. Telix Pharmaceuticals has a twelve month low of $5.91 and a twelve month high of $12.50. The stock has a fifty day simple moving average of $10.54 and a 200 day simple moving average of $9.38.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.00.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.